Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 ROE % is 26.35% as of Dec. 2025, which is 13% above its 10-year median of 23.27. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $0.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 937 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 91.68% on this metric.
The historical rank and industry rank for Consun Pharmaceutical Group's ROE % or its related term are showing as below:
CPHGF'
s ROE % Range Over the Past 10 Years
Min: 3.8 Med: 23.27 Max: 25.38
Current: 25.15
During the past 13 years, Consun Pharmaceutical Group's highest ROE % was 25.38%. The lowest was 3.80%. And the median was 23.27%.
CPHGF's ROE % is ranked better than 91.68% of 937
companies
in the Drug Manufacturers industry
Industry Median: 6.06
vs CPHGF: 25.15
Consun Pharmaceutical Group (OTCPK:CPHGF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's ROE % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Consun Pharmaceutical Group (CPHGF) has a ROE % of 26.35% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Consun Pharmaceutical Group and its competitors. This is 13% above median its historical median of 23.27. Over the past decade, Consun Pharmaceutical Group's ROE % has ranged from 3.80 to 25.38. According to the industry distribution chart, Consun Pharmaceutical Group ranks #78 out of 937 companies in the Drug Manufacturers industry, placing it in the top 8.3%.
Is Consun Pharmaceutical Group's ROE % too high?
Consun Pharmaceutical Group's current ROE % of 26.35% is 13% above median its 10-year median of 23.27. Over the past 10 years, this metric has ranged from a low of 3.80 to a high of 25.38. The Drug Manufacturers industry median ROE % is 6.06. Consun Pharmaceutical Group's value of 26.35% is 334.8% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #78 out of 937 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #78 out of 937 companies for ROE %. This places Consun Pharmaceutical Group in the top 8% of its industry — outperforming the majority of peers. The industry median ROE % is 6.06. Consun Pharmaceutical Group's value of 26.35% is 334.8% above this benchmark. Historically, Consun Pharmaceutical Group's own ROE % has ranged from 3.80 to 25.38 over the past decade. While the company's 10-year median is 23.27 vs. the industry median of 6.06, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.06, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current ROE % of 26.35% is 334.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current ROE % is 26.35%, which is 13% above median its own 10-year median of 23.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.80 — trading 200% above its estimated fair value. The current ROE % is 26.35%, which is 13% above median its 10-year median of 23.27 and 334.8% above the Drug Manufacturers industry median of 6.06. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current ROE % is 26.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 200% above its estimated GF Value™ of $0.60.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
ROE %: 26.35% (13% above median its 10-year median of 23.27)
GF Value™: $0.60 vs. price of $1.80 (200% above fair value)
Industry Position: 334.8% above the Drug Manufacturers median (#78 of 937)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
